Prevention effect of allopurinol on post-endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of prospective randomized controlled trials

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Cao, Wei Li ^a,b   Yan, Wen Shan ^a,b   Xiang, Xiao Hui ^b   Chen, Kai ^b   Xia, Shi Hai ^a,b  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; PLACEBO;

ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; INCIDENCE; LOW DRUG DOSE; META ANALYSIS; OUTCOME ASSESSMENT; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADVERSE EFFECTS; PROSPECTIVE STUDY;

ALLOPURINOL; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; HUMANS; INCIDENCE; PANCREATITIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84929942102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107350     Document Type: Article

References (28)

1. Dumonceau JM, Andriulli A, Deviere J, Mariani A, Rigaux J, et al. (2010) European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy 42: 503-515.
2. Nordback IH, Cameron JL (1993) The mechanism of conversion of xanthine dehydrogenase to xanthine oxidase in acute pancreatitis in the canine isolated pancreas preparation. Surgery 113: 90-97.
3. Sanfey H, Bulkley GB, Cameron JL (1984) The role of oxygen-derived free radicals in the pathogenesis of acute pancreatitis. Ann Surg 200: 405-413.
4. Sanfey H, Bulkley GB, Cameron JL (1985) The pathogenesis of acute pancreatitis. The source and role of oxygen-derived free radicals in three different experimental models. Ann Surg 201: 633-639.
5. Sanfey H, Cameron JL (1984) Increased capillary permeability: an early lesion in acute pancreatitis. Surgery 96: 485-491.
6. Masci E, Cavallini G, Mariani A, Frulloni L, Testoni PA, et al. (2003) Comparison of two dosing regimens of gabexate in the prophylaxis of post- ERCP pancreatitis. Am J Gastroenterol 98: 2182-2186.
7. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, et al. (1996) Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy-Italian Group. N Engl J Med 335: 919-923.
8. Kountouras J, Chatzopoulos D, Zavos C (2001) Reactive oxygen metabolites and upper gastrointestinal diseases. Hepatogastroenterology 48: 743-751.
9. Guan W, Osanai T, Kamada T, Hanada H, Ishizaka H, et al. (2003) Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol 41: 699-705.
10. Budzynska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E (2001) A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 33: 766-772.
11. Mosler P, Sherman S, Marks J, Watkins JL, Geenen JE, et al. (2005) Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc 62: 245-250.
12. Katsinelos P, Kountouras J, Chatzis J, Christodoulou K, Paroutoglou G, et al. (2005) High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial. Gastrointest Endosc 61: 407-415.
13. Romagnuolo J, Hilsden R, Sandha GS, Cole M, Bass S, et al. (2008) Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol 6: 465-471; quiz 371.
14. Martinez-Torres H, Rodriguez-Lomeli X, Davalos-Cobian C, Garcia-Correa J, Maldonado-Martinez JM, et al. (2009) Oral allopurinol to prevent hyperamylasemia and acute pancreatitis after endoscopic retrograde cholangiopancreatography. World J Gastroenterol 15: 1600-1606.
15. Abbasinazari M, Mohammad AAH, Moshiri K, Pourhoseingholi MA, Zali MR (2011) Does allopurinol prevent post endoscopic retrograde cholangiopancreatography pancreatitis? A randomized double blind trial. Acta Med Iran 49: 579-583.
16. Zheng M, Chen Y, Bai J, Xin Y, Pan X, et al. (2008) Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas 37: 247-253.
17. Bai Y, Gao J, Zhang W, Zou D, Li Z (2008) Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther 28: 557-564.
18. Higgins JPT, Green S (editors) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration.
19. Kountouras J, Chatzopoulos D, Zavos C (2001) Reactive oxygen metabolites and upper gastrointestinal diseases. Hepatogastroenterology 48: 743-751.
20. Pacher P, Nivorozhkin A, Szabo C (2006) Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58: 87-114.
21. Dumonceau JM, Andriulli A, Deviere J, Mariani A, Rigaux J, et al. (2010) European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy 42: 503-515.
22. Cheung J, Tsoi KK, Quan WL, Lau JY, Sung JJ (2009) Guidewire versus conventional contrast cannulation of the common bile duct for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis. Gastrointest Endosc 70: 1211-1219.
23. Sofuni A, Maguchi H, Itoi T, Katanuma A, Hisai H, et al. (2007) Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol 5: 1339-1346.
24. Freeman ML, Overby C, Qi D (2004) Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc 59: 8-14.
25. Arata S, Takada T, Hirata K, Yoshida M, Mayumi T, et al. (2010) Post-ERCP pancreatitis. J Hepatobiliary Pancreat Sci 17: 70-78.
26. Freeman ML, Guda NM (2004) Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 59: 845-864.
27. Pacher P, Nivorozhkin A, Szabo C (2006) Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58: 87-114.
28. Fathallah N, Ben SC, Slim R, Kaabia N, Letaief A, et al. (2010) Fatal allopurinol-induced hypersensitivity syndrome associated with pancreatic abnormalities. J Clin Rheumatol 16: 170-171.